Potential therapeutic applications of tetrahydrobiopterin: From inherited hyperphenylalaninemia to mitochondrial diseases

Annals of the New York Academy of Sciences

Volumn 1201, Issue , 2010, Pages 177-182

  Kim, Hyoung K ^a   Ha, Seung H ^a   Han, Jin ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

hyperphenylalaninemia; mitochondria; nitric oxide synthase; tetrahydrobiopterin

Indexed keywords

NEUROTRANSMITTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TETRAHYDROBIOPTERIN; 5,6,7,8-TETRAHYDROBIOPTERIN; ANTIOXIDANT; BIOPTERIN; DRUG DERIVATIVE;

ALZHEIMER DISEASE; CONFERENCE PAPER; DEVELOPMENTAL DISORDER; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; ENZYME DEFICIENCY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERPHENYLALANINEMIA; HYPERTENSION; HYPERTROPHY; ISCHEMIC HEART DISEASE; MEMBRANE POTENTIAL; MENTAL DEFICIENCY; MITOCHONDRIAL DNA DISORDER; MOTOR DYSFUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE PHOSPHORYLATION UNCOUPLING; OXIDATIVE STRESS; PARKINSON DISEASE; RESPIRATORY CHAIN; SEIZURE; TREATMENT OUTCOME; ANIMAL; BINDING SITE; BIOLOGICAL MODEL; DEGENERATIVE DISEASE; GENETICS; METABOLISM; MITOCHONDRION; MOUSE; MUTATION; PATHOLOGY; PHENYLKETONURIA; REVIEW; TRANSGENIC MOUSE;

ANIMALS; ANTIOXIDANTS; BINDING SITES; BIOPTERIN; HUMANS; MICE; MICE, TRANSGENIC; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MODELS, BIOLOGICAL; MUTATION; NEURODEGENERATIVE DISEASES; PHENYLKETONURIAS; REACTIVE OXYGEN SPECIES;

EID: 77955300639     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05623.x     Document Type: Conference Paper

References (40)

1. Thony, B., G. Auerbach & N. Blau. 2000. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem. J. 347(Pt 1): 1-16.
2. Knowles, R.G. & S. Moncada. 1994. Nitric oxide synthases in mammals. Biochem. J. 298(Pt 2): 249-258.
3. Wever, R.M. et al. 1997. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem. Biophys. Res. Commun. 237: 340-344.
4. Kotsonis, P. et al. 2000. Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterinandsuppression of auto-damaging superoxide. Biochem. J. 346(Pt 3): 767-776.
5. Scriver, C.R. 1995. Whatever happened to PKU? Clin. Biochem. 28: 137-144.
6. Kaufman, S. et al. 1975. Phenylketonuria due to a deficiency of dihydropteridine reductase.N.Engl. J.Med. 293: 785-790.
7. Ponzone, A. et al. 2004. Dihydropteridine reductase deficiency in man: from biology to treatment. Med. Res. Rev. 24: 127-150.
8. Shintaku, H. 2002. Disorders of tetrahydrobiopterin metabolism and their treatment. Curr. Drug. Metab. 3: 123-131.
9. Laursen, J.B. et al. 2001. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 103: 1282-1288.
10. Blau, N., L. Bonafe & B. Thony. 2001. Tetrahydrobiopterin deficiencies without hyperphenylalaninemia: diagnosis and genetics of Dopa-responsive dystonia and sepiapterin reductase deficiency. Mol. Genet. Metab. 74: 172-185.
11. Dumitrescu, C. et al. 2007. Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4. P. Natl. Acad. Sci. USA 104: 15081-15086.
12. Alp, N.J. & K.M. Channon. 2004. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler. Thromb. Vasc. Biol. 24: 413-420.
13. Cai, H. & D.G. Harrison. 2000. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87: 840-844.
14. Elrod, J.W. et al. 2006. eNOS gene therapy exacerbates hepatic ischemia-reperfusion injury in diabetes: a role for eNOS uncoupling. Circ. Res. 99: 78-85.
15. Stroes, E. et al. 1997. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J. Clin. Invest. 99: 41-46.
16. Xu, J. et al. 2007. Proteasome-dependent degradation of guanosine 5'-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetesmellitus. Circulation 116: 944-953.
17. Maier, W. et al. 2000. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J. Cardiovasc. Pharmacol. 35: 173-178.
18. Kase, H. et al. 2005. Supplementation with tetrahydrobiopterin prevents the cardiovascular effects of angiotensin II-induced oxidative and nitrosative stress. J. Hypertens. 23: 1375-1382.
19. Madeddu, P. 2005. Correction of endothelial dysfunction by tetrahydrobiopterin: new hope for the treatment of arterial hypertension? J. Hypertens. 23: 1335-1336.
20. Wajima,T. et al. 2006.Reduction ofmyocardial infarct size by tetrahydrobiopterin: possible involvement of mitochondrial KATP channels activation through nitric oxide production. J. Cardiovas. Pharmacol. 47: 243-249.
21. Foxton, R.H., J.M. Land & S.J. Heales. 2007. Tetrahydrobiopterin availability in Parkinson's and Alzheimer's disease; potential pathogenic mechanisms. Neurochem. Res. 32: 751-756.
22. Lovenberg, W. et al. 1979. Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease. Science 204: 624-626.
23. Williams, A.C. et al. 1980. CFS hydroxylase cofactor levels in some neurological diseases. J.Neurol. Neurosurg. Psychiatry. 43: 735-738.
24. Barford, P.A. et al. 1984. Tetrahydrobiopterin metabolism in the temporal lobe of patients dying with senile dementia of Alzheimer type. J. Neurol. Neurosurg. Psychiatry 47: 736-738.
25. Koshimura, K. et al. 2000. The role of 6R-tetrahydrobiopterin in the nervous system. Prog. Neurobiol. 61: 415-438.
26. Delp, M.D. et al. 2008. Ageing diminishes endotheliumdependent vasodilatation and tetrahydrobiopterin content in rat skeletal muscle arterioles. J. Physiol. 586: 1161-1168.
27. Higashi, Y. et al. 2006. Tetrahydrobiopterin improves agingrelated impairment of endothelium-dependent vasodilation through increase in nitric oxide production. Atherosclerosis 186: 390-395.
28. Rembold, H. & K. Buff. 1972. Tetrahydrobiopterin, a cofactor in mitochondrial electron transfer. Effect of tetrahydropterins on intact rat-liver mitochondria. Eur. J. Biochem. 28: 579-585.
29. Rembold, H. & K. Buff. 1972. Tetrahydrobiopterin, a cofactor in mitochondrial electron transfer. A soluble transfer system. Eur. J. Biochem. 28: 586-591.
30. Poderoso, J.J. et al. 1996. Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles. Arch. Biochem. Biophys. 328: 85-92.
31. Takehara, Y. et al. 1995. Oxygen-dependent regulation of mitochondrial energy metabolism by nitric oxide. Arch. Biochem. Biophys. 323: 27-32.
32. Nisoli, E. et al. 2003. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 299: 896-899.
33. Nisoli, E. et al. 2004.Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. Proceedings of the National Academy of Sciences of the United States of America 101: 16507-16512.
34. Ghafourifar, P. & C. Richter. 1997. Nitric oxide synthase activity in mitochondria. FEBS Lett. 418: 291-296.
35. Ghafourifar, P. & C. Richter. 1999.Mitochondrial nitric oxide synthase regulatesmitochondrialmatrix pH. Biol. Chem. 380: 1025-1028.
36. Ghafourifar, P. et al. 2001. Mitochondrial nitric oxide synthase, oxidative stress and apoptosis. Biol. Signals. Recept. 10: 57-65.
37. Delgado-Esteban, M., A. Almeida & J.M. Medina. 2002. Tetrahydrobiopterin deficiency increases neuronal vulnerability to hypoxia. J. Neurochem. 82: 1148-1159.
38. Nakamura, K. et al. 2001. Tetrahydrobiopterin scavenges superoxide in dopaminergic neurons. J. Biol. Chem. 276: 34402-34407.
39. Kim, H.L. et al. 2007.Tetrahydropteridine deficiency impairs mitochondrial function in Dictyostelium discoideum Ax2. FEBS Lett. 581: 5430-5434.
40. Yang, S. et al. 2006. Amurine model for human sepiapterinreductase deficiency. Am. J. Hum. Genet. 78: 575-587.